Back to search results

JV-394 for Relapsed or Refractory T/NK Cell Neoplasms

This study is testing a treatment called JV-394, which is a type of CAR-T cell therapy. This therapy uses your own immune cells, modified in a lab, to fight cancer. The main goal is to find the safest and most effective dose of JV-394 for people with T/NK cell lymphoma that has come back or hasn't responded to other treatments. Researchers will also look at how well JV-394 works and any side effects it might cause. You may be able to join if you are 18 or older, have a confirmed T/NK cell malignancy, and your cancer has relapsed or is refractory after at least one previous treatment. The study is currently recruiting about 33 participants.

Study design
This is an interventional study with a planned enrollment of 33 participants. It aims to determine the safety and identify the maximum tolerated dose of JV-394.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Safety and adverse events will be measured through study completion, which is an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07382817

Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms

Recruiting
PHASE1Ages 18+InterventionalTreatment
M.D. Anderson Cancer Center
~33 participants
Updated 2026-08-12 on ClinicalTrials.gov
What's tested:JV-394

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and Adverse Events (AEs)
Measured over Through study completion; an average of 1 year

Conditions

Neoplasms

Explore related trials

Enteropathy-associated TCLEpstein-Barr virus (EBV)+ nodal T/NK cell lymphomaExtranodal NK/TCLHepatosplenic TCLMonomorphic Epitheliotropic Intestinal T-Cell LymphomaNasal Type Extranodal NK/T-Cell LymphomaPeripheral TCL cytotoxic typePrimary cutaneous CD8+ aggressive epidermotropic cytotoxic TCLPrimary cutaneous γδ TCLSubcutaneous Panniculitis-Like T-Cell LymphomaNatural Killer Cells Antigen CD94

NCT07382817

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • The University of Texas M. D. Anderson Cancer Center

    Houston, Texasstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Sattva S Neelapu, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Sattva S Neelapu, MD
[email protected]
(713) 563-3429
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Safety and Adverse Events (AEs)Through study completion; an average of 1 year

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0